Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases

References

• who.int [Internet]. Chronic obstructive pulmonary disease (COPD). [cited 2022 May 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)).
   Google Scholar
• who.int [Internet]. Cancer. [cited 2022 Feb 3]. Available from:https://www.who.int/news-room/fact-sheets/detail/cancer
   Google Scholar
• who.int [Internet]. Asthma. [cited 2022 May 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
   Google Scholar
• Bierlaagh MC, Muilwijk D, Beekman JM. van der Ent CK. A new era for people with cystic fibrosis. Eur J Pediatr. 2021;180(9):2731–2739.
   PubMed Web of Science ®Google Scholar
• Turcios NL. Cystic fibrosis lung disease: an overview. Respir Care. 2020;65(2):233–251.
   PubMed Web of Science ®Google Scholar
• Keil TWM, Baldassi D, Merkel OM. T-cell targeted pulmonary siRNA delivery for the treatment of asthma. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12:5.
   Web of Science ®Google Scholar
• Shukla SD, Swaroop Vanka K, Chavelier A, et al. Chronic respiratory diseases: an introduction and need for novel drug delivery approaches. In: Dua K, Hansbro PM, Wadhwa R, editors. Targeting chronic inflammatory lung diseases using advanced drug delivery systems. Academic Press. 2020. p. 1–31.
   Google Scholar
• Rennard SI, Fogarty C, Kelsen S, et al. COPD Investigators. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration. 2011;81(4):265–284.
   PubMed Web of Science ®Google Scholar
• Szilasi M, Dolinay T, Nemes Z, et al. Pathology of chronic obstructive pulmonary disease. Pathol Oncol Res. 2006;12(1):52–60.
   PubMed Web of Science ®Google Scholar
• Punturieri A, Szabo E, Croxton TL, et al. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009;101(8):554–559.
   PubMedGoogle Scholar
• Xu Y, Thakur A, Zhang Y, et al. Inhaled RNA therapeutics for obstructive airway diseases: recent advances and future prospects. Pharmaceutics. 2021;13(2):1–35.
   Web of Science ®Google Scholar
• Westermann L, Neubauer B, Köttgen M. Nobel Prize 2020 in chemistry honors CRISPR: a tool for rewriting the code of life. Pflugers Arch. 2021;473:1.
   PubMed Web of Science ®Google Scholar
• Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–821.
   PubMed Web of Science ®Google Scholar
• Anders C, Niewoehner O, Duerst A, et al. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature. 2014;513(7519):569–573.
   PubMed Web of Science ®Google Scholar
• Jinek M, Jiang F, Taylor DW, et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science. 2014;343(6176):1247997.
   PubMed Web of Science ®Google Scholar
• international.neb.com [internet]. Genome editing glossary. [cited 2022 Sep 25]. Available from: https://international.neb.com/applications/genome-editing/genome-editing-glossary
   Google Scholar
• Leonova EI, Gainetdinov RR. CRISPR/Cas9 technology in translational biomedicine. Cell Physiol Biochem. 2020;54(3):354–370.
   PubMedGoogle Scholar
• Garneau JE, Dupuis M-E, Villion M, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010;468(7320):67–71.
   PubMed Web of Science ®Google Scholar
• Magadan AH, Dupuis M-E, Villion M, et al. Cleavage of phage DNA by the Streptococcus thermophilus CRISPR3-Cas system. PLoS One. 2012;7(7):e40913.
   PubMed Web of Science ®Google Scholar
• Lin S, Staahl BT, Alla RK, et al. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife. 2014;3:e04766.
   PubMed Web of Science ®Google Scholar
• Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281–2308.
   PubMed Web of Science ®Google Scholar
• Yip BH. Recent Advances in CRISPR/Cas9 delivery strategies. Biomolecules. 2020;10:6.
   Web of Science ®Google Scholar
• Heyer W-D, Ehmsen KT, Liu J. Regulation of homologous recombination in eukaryotes. Annu Rev Genet. 2010;44:113–139.
   PubMed Web of Science ®Google Scholar
• Orthwein A, Fradet-Turcotte A, Noordermeer SM. Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. Science. 2014;344(6180):189–193.
   PubMed Web of Science ®Google Scholar
• Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008;18(1):134–147.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Tsunekawa Y, Hernandez-Benitez R, et al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature. 2016;540(7631):144–149.
   PubMed Web of Science ®Google Scholar
• Yang W, Yan J, Zhuang P, et al. Progress of delivery methods for CRISPR-Cas9. Expert Opin Drug Deliv. 2022;19(8):1–14.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang ZT, Seo SO, et al. Bacterial genome editing with CRISPR-Cas9: deletion, integration, single nucleotide modification, and desirable ‘clean’ mutant selection in clostridium beijerinckii as an example. ACS Synth Biol. 2016;5(7):721–732.
   PubMed Web of Science ®Google Scholar
• Das J, Bhatia P, Singh A. CRISP points on establishing CRISPR- Cas9 in vitro culture experiments in a resource constraint haematology oncology research lab. Indian J Hematol Blood Transfus. 2019;35(2):208–214.
   PubMed Web of Science ®Google Scholar
• Xu X, Liu C, Wang Y, et al. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Adv Drug Deliv Rev. 2021;176:113891.
   PubMed Web of Science ®Google Scholar
• Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;351(6268):84–88.
   PubMed Web of Science ®Google Scholar
• Wilson LOW, O’Brien AR, Bauer DC. The current state and future of CRISPR-Cas9 gRNA design tools. Front Pharmacol. 2018;9:749.
   PubMed Web of Science ®Google Scholar
• Tyagi S, Kumar R, Das A, et al. CRISPR-Cas9 system: a genome-editing tool with endless possibilities. J Biotechnol. 2020;319:36–53.
   PubMed Web of Science ®Google Scholar
• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):9–16.
   Web of Science ®Google Scholar
• Mehravar M, Shirazi A, Nazari M, et al. Mosaicism in CRISPR/Cas9-mediated genome editing. Dev Biol. 2019;445(2):156–162.
   PubMed Web of Science ®Google Scholar
• Janik E, Niemcewicz M, Ceremuga M, et al. Various aspects of a gene editing system-CRISPR-Cas9. Int J Mol Sci. 2020;21:24.
   Web of Science ®Google Scholar
• Duan L, Ouyang K, Xu X, et al. Nanoparticle delivery of CRISPR/Cas9 for genome editing. Front Genet. 2021;12:673286.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim D, Cho SW, et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24(6):1012–1019.
   PubMed Web of Science ®Google Scholar
• Rui Y, Wilson DR, Choi J. Carboxylated branched poly(β-amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci Adv. 2019;5:12.
   Web of Science ®Google Scholar
• Liu X, Zhao Z, Wu F, et al. Tailoring hyperbranched Poly(β-amino ester) as a robust and universal platform for cytosolic protein delivery. Adv Mater. 2022;34:8.
   Web of Science ®Google Scholar
• Chuang CK, Lin WM. Points of view on the tools for genome/gene editing. Int J Mol Sci. 2021;22:18.
   Web of Science ®Google Scholar
• Cheng H, Zhang F, Ding Y. CRISPR/Cas9 delivery system engineering for genome editing in therapeutic applications. Pharmaceutics. 2021;13:10.
   Web of Science ®Google Scholar
• Filippova J, Matveeva A, Zhuravlev E, et al. Guide RNA modification as a way to improve CRISPR/Cas9-based genome-editing systems. Biochimie. 2019;167:49–60.
   PubMed Web of Science ®Google Scholar
• Fu Y, Foden JA, Khayter C, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822–826.
   PubMed Web of Science ®Google Scholar
• Anderson BR, Muramatsu H, Jha BK, et al. Nucleoside modifications in RNA limit activation of 2’-5’-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 2011;39(21):9329–9338.
   PubMed Web of Science ®Google Scholar
• Hendel A, Bak RO, Clark JT, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol. 2015;33(9):985–989.
   PubMed Web of Science ®Google Scholar
• Zu H, Non-viral GD. Vectors in gene therapy: recent development, challenges, and prospects. AAPS J. 2021;23:4.
   Web of Science ®Google Scholar
• Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng. 2015;17:63–89.
   PubMed Web of Science ®Google Scholar
• Lee CS, Bishop ES, Zhang R, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017;4(2):43–63.
   PubMed Web of Science ®Google Scholar
• Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther. 2004;15(12):1157–1166.
   PubMed Web of Science ®Google Scholar
• Hakim CH, Kumar SRP, Pérez-López DO, et al. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat Commun. 2021;12(1):6769.
   PubMed Web of Science ®Google Scholar
• Liang SQ, Walkey CJ, Martinez AE, et al. AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway. Mol Ther. 2022;30(1):238–243.
   PubMed Web of Science ®Google Scholar
• Kenjo E, Hozumi H, Makita Y, et al. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun. 2021;12:1.
   PubMed Web of Science ®Google Scholar
• Kazemian P, Yu SY, Thomson SB, et al. Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components. Mol Pharm. 2022;19(6):1669–1686.
   PubMed Web of Science ®Google Scholar
• Bond ML, Craparo EF. Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art. Expert Opin Drug Deliv. 2010;7(1):7–18.
   PubMed Web of Science ®Google Scholar
• Ryu N, Kim MA, Effective PD. PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy. Nanomedicine. 2018;14(7):2095–2102.
   PubMed Web of Science ®Google Scholar
• Zielinska A, Carreiró F, Oliveira AM, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25:16.
   Web of Science ®Google Scholar
• Ashok B, Peppas NA, Wechsler ME. Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9. J Drug Deliv Sci Technol. 2021;65:102728.
   PubMed Web of Science ®Google Scholar
• Xie R, Wang X, Wang Y, et al. pH-responsive polymer nanoparticles for efficient delivery of Cas9 ribonucleoprotein with or without donor DNA. Adv Mater. 2022;34:23.
   Web of Science ®Google Scholar
• Ma K, Li W, Zhu G, et al. Functionalized PDA/DEX-PEI@HA nanoparticles combined with sleeping-beauty transposons for multistage targeted delivery of CRISPR/Cas9 gene. Biomed Pharmacother. 2021;142:112061.
   PubMed Web of Science ®Google Scholar
• Liu C, Wan T, Wang H, et al. A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci Adv. 2019;5:6.
   Web of Science ®Google Scholar
• Ordóñez A, Harding HP, Marciniak SJ, et al. Cargo receptor-assisted endoplasmic reticulum export of pathogenic α1-antitrypsin polymers. Cell Rep. 2021;35:7.
   Web of Science ®Google Scholar
• Sun W, Ji W, Hall JM, et al. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed Engl. 2015;54(41):12029–12033.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang L, Xie Y. Genome editing for cancer therapy: delivery of Cas9 Protein/sgRNA plasmid via a gold nanocluster/lipid core-shell nanocarrier. Adv Sci (Weinh). 2017;4:11.
   Google Scholar
• Liu L, Li M, Xu M, et al. Actively targeted gold nanoparticle composites improve behavior and cognitive impairment in Parkinson’s disease mice. Mater Sci Eng C Mater Biol Appl. 2020;114:111028.
   PubMed Web of Science ®Google Scholar
• Mout R, Rotello V. Cytosolic and nuclear delivery of CRISPR/Cas9-ribonucleoprotein for gene editing using arginine functionalized gold nanoparticles. Biol Protoc. 2017;7(20):e2586.
   PubMedGoogle Scholar
• Usman WM, Pham TC, Kwok YY, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018;9(1):2359.
   PubMed Web of Science ®Google Scholar
• Alsaiari SK, Patil S, Alyami M, et al. Endosomal escape and delivery of CRISPR/Cas9 genome editing machinery enabled by nanoscale zeolitic imidazolate framework. J Am Chem Soc. 2018;140(1):143–146.
   PubMed Web of Science ®Google Scholar
• Gong J, Wang HX, Lao YH. A Versatile Nonviral. Delivery system for multiplex gene-editing in the liver. Adv Mater. 2020;32:46.
   Web of Science ®Google Scholar
• Yue H, Zhou X, Cheng M, et al. Graphene oxide-mediated Cas9/sgRNA delivery for efficient genome editing. Nanoscale. 2018;10(3):1063–1071.
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(7089):111–114.
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against zika virus infection. Cell. 2017;168(6):1114–1125.e10.
   PubMed Web of Science ®Google Scholar
• Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51(34):8529–8533.
   PubMed Web of Science ®Google Scholar
• Patel S, Ashwanikumar N, Robinson E, et al. Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA. Nano Lett. 2017;17(9):5711–5718.
   PubMed Web of Science ®Google Scholar
• Yan Y, Liu XY, Lu A, et al. Non-viral vectors for RNA delivery. J Control Release. 2022;342:241–279.
   PubMed Web of Science ®Google Scholar
• Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv Drug Deliv Rev. 2020;154-155:37–63.
   PubMed Web of Science ®Google Scholar
• Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008;26(5):561–569.
   PubMed Web of Science ®Google Scholar
• Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084–1087.
   PubMed Web of Science ®Google Scholar
• Semple SC, Klimuk SK, Harasym TO, et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta. 2001;1510(1–2):152–166.
   PubMed Web of Science ®Google Scholar
• Cho SW, Goldberg M, Son SM, et al. Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells. Adv Funct Mater. 2009;19(19):3112–3118.
   PubMed Web of Science ®Google Scholar
• Kulkarni JA, Cullis PR, Van Der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28(3):146–157.
   PubMed Web of Science ®Google Scholar
• Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci U S A. 2021;118(52):e2109256118.
   PubMedGoogle Scholar
• Zhang D, Wang G, Yu X, et al. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat Nanotechnol. 2022;17(7):777–787.
   PubMed Web of Science ®Google Scholar
• Miller JB, Zhang S, Kos P, et al. Non-viral CRISPR/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle Co-delivery of Cas9 mRNA and sgRNA. Angew Chem Int Ed Engl. 2017;56(4):1059–1063.
   PubMed Web of Science ®Google Scholar
• Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172–176.
   PubMed Web of Science ®Google Scholar
• Song LY, Ahkong QF, Rong Q, et al. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta. 2002;1558(1):1–13.
   PubMed Web of Science ®Google Scholar
• Belliveau NM, Huft J, Lin PJ, et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids. Published 2012 Aug 14. 2012;1(8):e37.
   PubMedGoogle Scholar
• Leung AK, Tam YY, Chen S, et al. Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. J Phys Chem B. 2015;119(28):8698–8706.
   PubMed Web of Science ®Google Scholar
• Roces CB, Lou G, Jain N, et al. Manufacturing considerations for the development of lipid nanoparticles using microfluidics. Pharmaceutics. Published 2020 Nov 15. 2020;12(11):1095.
   PubMed Web of Science ®Google Scholar
• Mui BL, Tam YK, Jayaraman M, et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic Acids. 2013;2(12):e139.
   PubMedGoogle Scholar
• Zhang X, Goel V, Robbie GJ. Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis. J Clin Pharmacol. 2020;60(5):573–585.
   PubMed Web of Science ®Google Scholar
• Li C, Yang T, Weng Y, et al. Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. Bioact Mater. 2022;9:590–601.
   PubMed Web of Science ®Google Scholar
• Liu J, Chang J, Jiang Y, et al. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles. Adv Mater. 2019;31(33):33.
   Web of Science ®Google Scholar
• Rothgangl T, Dennis MK, Lin PJC, et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat Biotechnol. 2021;39(8):949–957.
   PubMed Web of Science ®Google Scholar
• Villiger L, Rothgangl T, Witzigmann D, et al. In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA. Nat Biomed Eng. 2021;5(2):179–189.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493–502.
   PubMed Web of Science ®Google Scholar
• Qiu M, Glass Z, Chen J, et al. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3. Proc Natl Acad Sci U S A. 2021;118(10):10.
   Web of Science ®Google Scholar
• Wang M, Zuris JA, Meng F, et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci U S A. 2016;113(11):2868–2873.
   PubMed Web of Science ®Google Scholar
• Yang S, Chang R, Yang H, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. J Clin Invest. 2017;127(7):2719–2724.
   PubMed Web of Science ®Google Scholar
• Kulkarni JA, Myhre JL, Chen S, et al. Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine. 2017;13(4):1377–1387.[90].
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang P, Feng Q, et al. Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy. NPG Asia Mater. 2017;9(10):e441–e441.
   Google Scholar
• Han JP, Kim M, Choi BS, et al. In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy. Sci Adv. 2022;8(3):eabj6901.
   PubMed Web of Science ®Google Scholar
• Finn JD, Smith AR, Patel MC, et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018;22(9):2227–2235.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Wei T, Farbiak L, et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313–320.
   PubMed Web of Science ®Google Scholar
• Lee AY, Cho M-H, Kim S. Recent advances in aerosol gene delivery systems using non-viral vectors for lung cancer therapy. Expert Opin Drug Deliv. 2019;16(7):757–772.
   PubMed Web of Science ®Google Scholar
• Robinson E, MacDonald KD, Slaughter K, et al. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Mol Ther. 2018;26(8):2034–2046.
   PubMed Web of Science ®Google Scholar
• Parhiz H, Shuvaev VV, Pardi N, et al. PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake. J Control Release. 2018;291:106–115.
   PubMed Web of Science ®Google Scholar
• Wei T, Cheng Q, Min Y-L, et al. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020;11(1):1–12.
   PubMed Web of Science ®Google Scholar
• Osman N, Kaneko K, Carini V, et al. Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies. Expert Opin Drug Deliv. 2018;15(8):821–834.
   PubMed Web of Science ®Google Scholar
• Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015;219:500–518.
   PubMed Web of Science ®Google Scholar
• Abdelaziz HM, Gaber M, Abd-Elwakil MM, et al. Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018;269:374–392.
   PubMed Web of Science ®Google Scholar
• Agu RU, Ugwoke MI, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001;2(4):198–209.
   PubMed Web of Science ®Google Scholar
• Malek A, Merkel O, Fink L, et al. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol. 2009;236(1):97–108.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14(4):499–512.
   PubMed Web of Science ®Google Scholar
• Munir M, Jena L, Kett VL, et al. Spray drying: inhalable powders for pulmonary gene therapy. Biometer Adv. 2022;133:112601
   PubMedGoogle Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–599.
   PubMed Web of Science ®Google Scholar
• Malamatari M, Charisi A, Malamataris S, et al. Spray drying for the preparation of nanoparticle-based drug formulations as dry powders for inhalation. Processes. 2020;8(7):788.
   Web of Science ®Google Scholar
• Murgia X, De Souza Carvalho C, Lehr CM. Overcoming the pulmonary barrier: new insights to improve the efficiency of inhaled therapeutics. Eur J Nanomed. 2014;6(3):157–169.
   Google Scholar
• Elsayed I, Aboughaly MHH. Inhalable nanocomposite microparticles: preparation, characterization and factors affecting formulation. Expert Opin Drug Deliv. 2016;13(2):207–222.
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131–139.
   PubMedGoogle Scholar
• Keil TWM, Feldmann DP, Costabile G, et al. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles. Eur J Pharm Biopharm. 2019;143:61–69.
   PubMed Web of Science ®Google Scholar
• Keil TWM, Zimmermann C, Baldassi D, et al. Impact of crystalline and amorphous matrices on successful spray drying of siRNA polyplexes for inhalation of nano-in-microparticles. Adv Ther (Weinh). 2021;4:6
   Google Scholar
• Xu Y, Harinck L, Lokras AG, et al. Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. Int J Pharm. 2022 621 ;121758.
   PubMedGoogle Scholar
• Craparo EF, Porsio B, Sardo C, et al. Nanoparticles penetrating cystic fibrosis artificial mucus. Biomacromolecules. 2016;17(3):767–777.
   PubMed Web of Science ®Google Scholar
• Costabile G, Provenzano R, Azzalin A, et al. PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against Burkholderia cenocepacia infection. Nanomedicine. 2020;23:102113.
   PubMed Web of Science ®Google Scholar
• Schuster BS, Suk JS, Woodworth GF, et al. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials. 2013;34(13):3439–3446.
   PubMed Web of Science ®Google Scholar
• Conte G, Costabile G, Baldassi D, et al. Hybrid lipid/polymer nanoparticles to tackle the cystic fibrosis mucus barrier in siRNA delivery to the lungs: does PEGylation make the difference? ACS Appl Mater Interfaces. 2022;14(6):7565–7578.
   PubMed Web of Science ®Google Scholar
• Chen D, Liu J, Wu J, et al. Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung. Expert Opin Drug Deliv. 2021;18(5):595–606.
   PubMed Web of Science ®Google Scholar
• Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences–clinical impact, mechanisms, and potential for early intervention. COPD. 2008;5(4):235–256.
   PubMedGoogle Scholar
• Brown JS, Bennett WD. Deposition of coarse particles in cystic fibrosis: model predictions versus experimental results. J Aerosol Med. 2004;17(3):239–248.
   PubMedGoogle Scholar
• Chow MYT, Chang RYK, Chan H-K. Inhalation delivery technology for genome-editing of respiratory diseases. Adv Drug Deliv Rev. 2021;168:217–228.
   PubMed Web of Science ®Google Scholar
• Kim N, Duncan GA, Hanes J, et al. Barriers to inhaled gene therapy of obstructive lung diseases: a review. J Control Release. 2016;240:465–488.
   PubMed Web of Science ®Google Scholar
• Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med. 2007;13(6):231–240.
   PubMed Web of Science ®Google Scholar
• Mastorakos P, da Silva AL, Chisholm J, et al. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci U S A. 2015;112(28):8720–8725.
   PubMed Web of Science ®Google Scholar
• Liang W, Kwok PCL, Chow MYT, et al. Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. Eur J Pharm Biopharm. 2014;86(1):64–73.
   PubMed Web of Science ®Google Scholar
• Ruge CA, Bohr A, Beck-Broichsitter M, et al. Disintegration of nano-embedded microparticles after deposition on mucus: a mechanistic study. Colloids Surf B Biointerfaces. 2016;139:219–227.
   PubMed Web of Science ®Google Scholar
• Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586.
   PubMed Web of Science ®Google Scholar
• Merkel OM. Can pulmonary RNA delivery improve our pandemic preparedness? J Control Release. 2022;345:549–556.
   PubMed Web of Science ®Google Scholar
• Chang RYK, Chow MYT, Khanal D, et al. Dry powder pharmaceutical biologics for inhalation therapy. Adv Drug Deliv Rev. 2021;172:64–79.
   PubMed Web of Science ®Google Scholar
• Chow MYT, Qiu Y, Lo FFK, et al. Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer. Int J Pharm. 2017;530(1–2):40–52.
   PubMedGoogle Scholar
• Wu J, Wu L, Wan F, et al. Effect of thermal and shear stresses in the spray drying process on the stability of siRNA dry powders. Int J Pharm. 2019;566:32–39.
   PubMed Web of Science ®Google Scholar
• Amaro MI, Tajber L, Corrigan OI, et al. Optimisation of spray drying process conditions for sugar nanoporous microparticles (NPMPs) intended for inhalation. Int J Pharm. 2011;421(1):99–109.
   PubMedGoogle Scholar
• LeClair DA, Cranston ED, Xing Z, et al. Optimization of spray drying conditions for yield, particle size and biological activity of thermally stable viral vectors. Pharm Res. 2016;33(11):2763–2776.
   PubMed Web of Science ®Google Scholar
• Dormenval C, Lokras A, Cano-Garcia G, et al. Identification of factors of importance for spray drying of small interfering RNA-loaded lipidoid-polymer hybrid nanoparticles for inhalation. Pharm Res. 2019;36:10.
   Web of Science ®Google Scholar
• Alhajj N, O’Reilly NJ, Cathcart H. Designing enhanced spray dried particles for inhalation: a review of the impact of excipients and processing parameters on particle properties. Powder Technol. 2021;384:313–331.
   Web of Science ®Google Scholar
• Fernandes DA, Costa E, Leandro P, et al. Formulation of spray dried enzymes for dry powder inhalers: an integrated methodology. Int J Pharm. 2022;615:1–8.
   Google Scholar
• Agnoletti M, Bohr A, Thanki K, et al. Inhalable siRNA-loaded nano-embedded microparticles engineered using microfluidics and spray drying. Eur J Pharm Biopharm. 2017;120:9–21.
   PubMed Web of Science ®Google Scholar
• Jensen DMK, Cun D, Maltesen MJ, et al. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release. 2010;142(1):138–145.
   PubMed Web of Science ®Google Scholar
• Jensen DK, Jensen LB, Koocheki S, et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release. 2012;157(1):141–148.
   PubMed Web of Science ®Google Scholar
• Wang JL, Hanafy MS, Xu H, et al. Aerosolizable siRNA-encapsulated solid lipid nanoparticles prepared by thin-film freeze-drying for potential pulmonary delivery. Int J Pharm. 2021;596:120215.
   PubMedGoogle Scholar
• Munir M, Kett VL, Dunne NJ, et al. Development of a spray-dried formulation of peptide-DNA nanoparticles into a dry powder for pulmonary delivery using factorial design. Pharm Res. 2022;39:6.
   Web of Science ®Google Scholar
• Schulze J, Kuhn S, Hendrikx S, et al. Spray-Dried Nanoparticle-in-Microparticle Delivery Systems (NiMDS) for Gene Delivery, Comprising Polyethylenimine (PEI)-based nanoparticles in a poly(vinyl alcohol) matrix. Small. 2018;14:12.
   Web of Science ®Google Scholar
• Vencken S, Foged C, Ramsey JM, et al. Nebulised lipid-polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells. ERJ Open Res. 2019;5:2.
   Google Scholar
• Chow MYT, Qiu Y, Liao Q, et al. High siRNA loading powder for inhalation prepared by co-spray drying with human serum albumin. Int J Pharm. 2019;572:118818.
   PubMedGoogle Scholar
• Kumari A, Pal S, Betsy Reshma G. Surface-engineered mucus penetrating nucleic acid delivery systems with cell penetrating peptides for the lungs. Mol Pharm. 2022;19(5):1309–1324.
   PubMedGoogle Scholar
• Kazemi Oskuee R, Dabbaghi M, Gholami L, et al. Investigating the influence of polyplex size on toxicity properties of polyethylenimine mediated gene delivery. Life Sci. 2018;197:101–108.
   PubMed Web of Science ®Google Scholar
• Nieto González N, Obinu A, Rassu G, et al. Polymeric and lipid nanoparticles: which applications in pediatrics? Pharmaceutics. 2021;13:5.
   Web of Science ®Google Scholar
• Lu H, Zhang S, Wang J, et al. A review on polymer and lipid-based nanocarriers and its application to nano-pharmaceutical and food-based systems. Front Nutr. 2021;8:1051.
   Web of Science ®Google Scholar
• Zimmermann CM, Baldassi D, Chan K, et al. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery [published online ahead of print, 2022 Sep 22]. J Control Release. 2022;351:137–150.
   PubMed Web of Science ®Google Scholar
• Karve S, DeRosa F, Heartlein M, et al., inventors. Translate Bio Inc, assignee. Dry powder formulations for messenger rna. United States patent US 2020/0022921 A1. 2020 Jan 23.
   Google Scholar
• Merkel OM, Keil T, Zimmermann CM, et al. Nano-in-Micro encapsulated siRNA dry powder, method for producing the same and use of a powder formulation. World Intellectual Property Organization WO; 2022/079105 A1. 2022 Apr 21.
   Google Scholar
• Kim W, Lee S, Kim HS, et al. Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. Genome Res. 2018;28(3):374–382.
   PubMed Web of Science ®Google Scholar